Non-steroidal anti-inflammatory drugs, prostaglandins, and COVID-19.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of the novel coronavirus disease 2019 (COVID-19), a highly pathogenic and sometimes fatal respiratory disease responsible for the current 2020 global pandemic. Presently, there remains no effective vaccine or efficient treatment strategies against COVID-19. Non-steroidal anti-inflammatory drugs (NSAIDs) are medicines very widely used to alleviate fever, pain, and inflammation (common symptoms of COVID-19 patients) through effectively blocking production of prostaglandins (PGs) via inhibition of cyclooxyganase enzymes. PGs can exert either proinflammatory or anti-inflammatory effects depending on the inflammatory scenario. In this review, we survey the potential roles that NSAIDs and PGs may play during SARS-CoV-2 infection and the development and progression of COVID-19. LINKED ARTICLES: This article is part of a themed issue on The Pharmacology of COVID-19. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v177.21/issuetoc.
['Robb|Calum T|CT|0000-0002-0249-7212', 'Goepp|Marie|M|', 'Rossi|Adriano G|AG|', 'Yao|Chengcan|C|0000-0003-3754-2842']
D000818:Animals D000894:Anti-Inflammatory Agents, Non-Steroidal D000073640:Betacoronavirus D000086382:COVID-19 D018352:Coronavirus Infections D018450:Disease Progression D006801:Humans D007249:Inflammation D058873:Pandemics D011024:Pneumonia, Viral D011453:Prostaglandins D000086402:SARS-CoV-2
prostaglandin COVID-19 SARS-CoV-2 NSAID inflammation cytokine storm